Last reviewed · How we verify
NCT03944421: MYCOMEAT
The Effects of Replacing Red and Processed Meat With Quorn on Biomarkers of Gut Health
NA trial testing Red and Processed Meat in Colorectal Cancer in 20 participants. Completed in 29 January 2020.
29 January 2020
Quick facts
| Lead sponsor | Northumbria University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 3 July 2019 |
| Primary completion | 29 January 2020 |
| Estimated completion | 29 January 2020 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Red and Processed Meat
- Quorn
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Northumbria University
Who can join
Adults 18 to 50, male only, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the effects of substituting red and processed meat in the diet with Quorn; a meat replacement product, on biomarkers of gut health. This will be a crossover design where participants will take part in 2 study periods where they will consume a diet containing red and processed meat during one of the study periods, whereas in the other study period, they will consume a diet containing Quorn.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Substituting meat for mycoprotein reduces genotoxicity and increases the abundance of beneficial microbes in the gut: Mycomeat, a randomised crossover control trial.
Farsi DN, Gallegos JL, Koutsidis G, Nelson A, et al · · 2023 · cited 22× · PMID 36651990 · DOI 10.1007/s00394-023-03088-x -
The effects of substituting red and processed meat for mycoprotein on biomarkers of cardiovascular risk in healthy volunteers: an analysis of secondary endpoints from Mycomeat.
Farsi DN, Gallegos JL, Finnigan TJA, Cheung W, et al · · 2023 · cited 8× · PMID 37624376 · DOI 10.1007/s00394-023-03238-1
Verify or expand the search:
- PubMed search for NCT03944421
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Northumbria University trials
Trials by the same sponsor.
- NCT07501611 — Acute Cardiovascular Effects of Transcutaneous Auricular Vagus Nerve Stimulation · NA · not yet recruiting
- NCT07242430 — 12-week Multi-vitamin/Mineral Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being · NA · not yet recruiting
- NCT07235878 — 12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being · NA · not yet recruiting
- NCT07297485 — Evaluating the Level of Agreement Between Goniometer Measurements and Algorithm to Determine Wall Squat Position · completed
- NCT06967454 — Manipulation of Whey Permeate Formulation for Better Fluid Retention. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03944421 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northumbria University
- Last refreshed: 1 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03944421.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing